Trial Profile
DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Dec 2020
Price :
$35
*
At a glance
- Drugs Amifampridine (Primary)
- Indications Brugada syndrome
- Focus Therapeutic Use
- Acronyms DAPREB
- 03 Dec 2020 Status changed from not yet recruiting to discontinued.
- 22 Jul 2008 New trial record.